Keywords: oncologycancerBreast CancerHead and Neck CancerNon Small Cell Lung CancerUnresectable or Metastatic MelanomaLymphomaBreast NeoplasmsTriple-Negative Breast NeoplasmsHormone Receptor Positive/HER2 Negative Breast NeoplasmsDiffuse Large B Cell LymphomaEsophageal CancerOvarian CancerCX-072CX-2009CX-801CX-2051CX-904CX-2029CX-188
Raise Follow-on offering: $250M (total, as published), announced Mar 18, 2026. Source: company release on GlobeNewswire. source ↗
Raise Follow-on offering: $100M (total, as published), announced May 12, 2025. Source: company release on GlobeNewswire. source ↗
Trial start Phase 1: First In Human Study of CX-801 in Advanced Solid Tumors source ↗
Trial start Phase 1: First In Human Study of CX-2051 in Advanced Solid Tumors source ↗
Trial start Phase 1: A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors source ↗
Trial start Phase 2: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer source ↗
Trial start Phase 1: PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors source ↗
Trial start Phase 2: PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors source ↗
Trial start Phase 1/Phase 2: PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL source ↗
Trial start Phase 1/Phase 2: PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors source ↗
Trial start Phase 1/Phase 2: PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas source ↗
Upcoming milestones
Nov 30, 2027 (ESTIMATED) · Phase 1 · First In Human Study of CX-2051 in Advanced Solid Tumors · NCT06265688
Feb 28, 2028 (ESTIMATED) · Phase 1 · First In Human Study of CX-801 in Advanced Solid Tumors · NCT06462794
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $350.0M. Last 2 years.
Follow-on offering: $250M (total, as published), announced Mar 18, 2026. Source: company release on GlobeNewswire. source ↗
Follow-on offering: $100M (total, as published), announced May 12, 2025. Source: company release on GlobeNewswire. source ↗
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
Phase 1
Withdrawn
2020-01
2020-12 (estimated)
NIH awards 2
Annual award amounts. Total $469K.
NIH award 1R43CA139790-01 FY2009: $260,910 awarded for that fiscal year; activity R43 (SBIR); PI WEST, JAMES W; recipient as written: CYTOMX THERAPEUTICS, INC., SOUTH SAN FRANCISCO, CA. Development of Probodies: A No source ↗
NIH award 1R43CA132498-01A1 FY2008: $208,046 awarded for that fiscal year; activity R43 (SBIR); PI BESSETTE, PAUL H; recipient as written: CYTOMX THERAPEUTICS, INC., SOUTH SAN FRANCISCO, CA. Discovery of a Novel, Int source ↗
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
